Tag: enoxaparin

1. Therapeutic anticoagulation with rivaroxaban or enoxaparin did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. 2. Net clinical benefit composite of death, thrombotic events, and major or clinically relevant non-major bleeding was not significantly different between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: COVID-19 is associated with...
1. For patients who underwent elective surgery and were at moderate to high risk of venous thromboembolism, pharmaco-thromboprophylaxis with low molecular weight heparin alone was noninferior to a combination of pharmaco-thromboprophylaxis and graduated compression stockings. Evidence Rating: 1 (Excellent) Venous thromboembolism (VTE) is associated with significant mortality and morbidity worldwide. For patients...
Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study 1. In three separate models, it was found that the combination of decreased health care access, food availability, and the economic impacts (both intentional and unintentional) of...
1. Anticoagulation at prophylactic dosing appeared to be associated with lower mortality and better prognosis in COVID-19 patients with coagulation dysfunction: i.e., sepsis-induced coagulopathy or a D-dimer greater than 6 times the upper limit or normal (30ug/mL). 2. No mortality benefit was found between heparin users and nonusers in other groups. Evidence...
1. Anticoagulation at prophylactic dosing appeared to be associated with lower mortality and better prognosis in COVID-19 patients with coagulation dysfunction: i.e., sepsis-induced coagulopathy or a D-dimer greater than 6 times the upper limit or normal (30ug/mL). 2. No mortality benefit was found between heparin users and nonusers other groups. Evidence...